Integra LifeSciences (NASDAQ:IART) Shares Gap Down – Time to Sell?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $19.76, but opened at $18.51. Integra LifeSciences shares last traded at $18.4080, with a volume of 114,181 shares traded.

Key Integra LifeSciences News

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q2 earnings beat expectations: Integra reported adjusted earnings of $0.56 per share, up from $0.45 a year earlier and above the $0.48 consensus estimate. Revenue of $418.8 million was also slightly ahead of expectations. Integra LifeSciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst price target raised: Wells Fargo increased its target from $15 to $18 while maintaining an “equal weight” rating. The higher target signals improved valuation expectations, although the unchanged rating limits the bullish impact. Wells Fargo raises Integra price target
• Positive Sentiment: Technical momentum remains favorable: IART was identified as a potential breakout stock after trading near its 52-week high and passing technical screens, which may attract momentum-oriented investors. Stocks showing breakout potential
• Neutral Sentiment: Full-year outlook was maintained near consensus: Integra expects 2026 EPS of $2.40-$2.50 and revenue of approximately $1.7 billion, broadly matching analyst expectations.
• Neutral Sentiment: New analyst coverage: UBS began coverage of Integra, adding institutional attention; the available report does not specify its rating or price target. UBS begins coverage on Integra LifeSciences
• Negative Sentiment: Q3 guidance offers limited upside: EPS guidance of $0.53-$0.61 and revenue guidance of $410 million-$425 million bracket consensus estimates, suggesting expectations are largely embedded rather than being raised. Integra also reported a negative net margin, underscoring ongoing profitability concerns.

Analyst Ratings Changes

A number of research analysts have recently issued reports on IART shares. Wall Street Zen downgraded shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Truist Financial boosted their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. UBS Group began coverage on shares of Integra LifeSciences in a report on Tuesday. They issued a “neutral” rating and a $19.00 target price on the stock. Finally, Wells Fargo & Company lifted their target price on Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a research note on Thursday. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $18.86.

Integra LifeSciences Price Performance

The company has a market capitalization of $1.33 billion, a P/E ratio of -189.95, a PEG ratio of 1.14 and a beta of 1.22. The company has a quick ratio of 1.95, a current ratio of 3.38 and a debt-to-equity ratio of 1.75. The business has a 50 day simple moving average of $17.67 and a 200-day simple moving average of $13.45.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.31%. The business had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IART. SG Americas Securities LLC acquired a new position in shares of Integra LifeSciences during the fourth quarter worth approximately $4,722,000. Hsbc Holdings PLC bought a new position in Integra LifeSciences in the 4th quarter worth approximately $879,000. Tejara Capital Ltd increased its position in Integra LifeSciences by 42.6% in the 4th quarter. Tejara Capital Ltd now owns 171,813 shares of the life sciences company’s stock valued at $2,134,000 after acquiring an additional 51,300 shares during the period. Systematic Financial Management LP increased its position in Integra LifeSciences by 4.5% in the 4th quarter. Systematic Financial Management LP now owns 1,108,599 shares of the life sciences company’s stock valued at $13,769,000 after acquiring an additional 48,094 shares during the period. Finally, UBS Group AG raised its stake in Integra LifeSciences by 211.7% during the 4th quarter. UBS Group AG now owns 408,969 shares of the life sciences company’s stock valued at $5,079,000 after acquiring an additional 277,745 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.